Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m
Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect o...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2024-03, Vol.16 (3), p.e57362-e57362 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e57362 |
|---|---|
| container_issue | 3 |
| container_start_page | e57362 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 16 |
| creator | Mima, Akira Gotoda, Hidemasa Lee, Shinji |
| description | Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m
. Methods Seven patients with CKD who received dotinurad 0.5 mg to 4 mg per day were studied retrospectively. Changes in UA, eGFR, and urine protein-to-creatinine ratio (UPCR) were analyzed. The observation period was 10.9±2.1 months. Results Serum UA levels were decreased and maintained with dotinurad administration. Nevertheless, there were no improvements noted in renal function. Additionally, no serious adverse effects were identified in any of the patients throughout the observation period. Conclusion Although the sample size in this study was small, our findings demonstrate the efficacy of dotinurad in individuals with advanced CKD who have an eGFR lower than 25 mL/min/1.73 m
. |
| doi_str_mv | 10.7759/cureus.57362 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11061547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3050174341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2152-716c11353205a8e71d7d8658e683845036a8cef57e7deb0e67ccc30ede88c32d3</originalsourceid><addsrcrecordid>eNpdkUtvEzEUhS1ERau0O9bIEhsWTeLH-JEVKmlaEEEgoGJpufYd4mrGLvZMq_yR_l5cUqrC6l7pHH265x6EXlIyU0os5m7MMJaZUFyyZ-iAUamnmurm-ZN9Hx2VckUIoUQxosgLtM-1XDQN5Qfo7pttYdhiGz1etW1w1m1xavFpGkIcs_U4RXyRg8MnLngcIv5ihwBxKPhHGDZ4uckpVvVj8BG2-DQUsAV22qoMobcDeHzepR7y2NmMz0I35Iqo2K9Vw--gS7eYCdyv559CnNOZ4rg_RHut7QocPcwJujhbfV--n64_n39YnqynjlHBpopKRykXnBFhNSjqlddSaJCa60YQLq120AoFysMlAamcc5yAB60dZ55P0Nsd93q87MG7GizbzlznenjemmSD-VeJYWN-phtDKZFUNKoS3jwQcvo1QhlMH4qDrrMR0lgMJ4JQ1fD67Ql6_Z_1Ko051nzVJZnmC87ugcc7l8uplAzt4zWUmPvSza5086f0an_1NMGj-W_F_Dcuz6hP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3062839327</pqid></control><display><type>article</type><title>Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Mima, Akira ; Gotoda, Hidemasa ; Lee, Shinji</creator><creatorcontrib>Mima, Akira ; Gotoda, Hidemasa ; Lee, Shinji</creatorcontrib><description>Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m
. Methods Seven patients with CKD who received dotinurad 0.5 mg to 4 mg per day were studied retrospectively. Changes in UA, eGFR, and urine protein-to-creatinine ratio (UPCR) were analyzed. The observation period was 10.9±2.1 months. Results Serum UA levels were decreased and maintained with dotinurad administration. Nevertheless, there were no improvements noted in renal function. Additionally, no serious adverse effects were identified in any of the patients throughout the observation period. Conclusion Although the sample size in this study was small, our findings demonstrate the efficacy of dotinurad in individuals with advanced CKD who have an eGFR lower than 25 mL/min/1.73 m
.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.57362</identifier><identifier>PMID: 38694413</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Cholesterol ; Creatinine ; Diabetes ; Drugs ; Ethics ; Females ; High density lipoprotein ; Internal Medicine ; Kidney diseases ; Medical records ; Nephrology ; Patients ; Pharmaceuticals ; Proteins ; Standard deviation ; Toxins ; Uric acid ; Urine</subject><ispartof>Curēus (Palo Alto, CA), 2024-03, Vol.16 (3), p.e57362-e57362</ispartof><rights>Copyright © 2024, Mima et al.</rights><rights>Copyright © 2024, Mima et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2024, Mima et al. 2024 Mima et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2152-716c11353205a8e71d7d8658e683845036a8cef57e7deb0e67ccc30ede88c32d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061547/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061547/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38694413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mima, Akira</creatorcontrib><creatorcontrib>Gotoda, Hidemasa</creatorcontrib><creatorcontrib>Lee, Shinji</creatorcontrib><title>Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m
. Methods Seven patients with CKD who received dotinurad 0.5 mg to 4 mg per day were studied retrospectively. Changes in UA, eGFR, and urine protein-to-creatinine ratio (UPCR) were analyzed. The observation period was 10.9±2.1 months. Results Serum UA levels were decreased and maintained with dotinurad administration. Nevertheless, there were no improvements noted in renal function. Additionally, no serious adverse effects were identified in any of the patients throughout the observation period. Conclusion Although the sample size in this study was small, our findings demonstrate the efficacy of dotinurad in individuals with advanced CKD who have an eGFR lower than 25 mL/min/1.73 m
.</description><subject>Cholesterol</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Drugs</subject><subject>Ethics</subject><subject>Females</subject><subject>High density lipoprotein</subject><subject>Internal Medicine</subject><subject>Kidney diseases</subject><subject>Medical records</subject><subject>Nephrology</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Proteins</subject><subject>Standard deviation</subject><subject>Toxins</subject><subject>Uric acid</subject><subject>Urine</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkUtvEzEUhS1ERau0O9bIEhsWTeLH-JEVKmlaEEEgoGJpufYd4mrGLvZMq_yR_l5cUqrC6l7pHH265x6EXlIyU0os5m7MMJaZUFyyZ-iAUamnmurm-ZN9Hx2VckUIoUQxosgLtM-1XDQN5Qfo7pttYdhiGz1etW1w1m1xavFpGkIcs_U4RXyRg8MnLngcIv5ihwBxKPhHGDZ4uckpVvVj8BG2-DQUsAV22qoMobcDeHzepR7y2NmMz0I35Iqo2K9Vw--gS7eYCdyv559CnNOZ4rg_RHut7QocPcwJujhbfV--n64_n39YnqynjlHBpopKRykXnBFhNSjqlddSaJCa60YQLq120AoFysMlAamcc5yAB60dZ55P0Nsd93q87MG7GizbzlznenjemmSD-VeJYWN-phtDKZFUNKoS3jwQcvo1QhlMH4qDrrMR0lgMJ4JQ1fD67Ql6_Z_1Ko051nzVJZnmC87ugcc7l8uplAzt4zWUmPvSza5086f0an_1NMGj-W_F_Dcuz6hP</recordid><startdate>20240331</startdate><enddate>20240331</enddate><creator>Mima, Akira</creator><creator>Gotoda, Hidemasa</creator><creator>Lee, Shinji</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240331</creationdate><title>Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m</title><author>Mima, Akira ; Gotoda, Hidemasa ; Lee, Shinji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2152-716c11353205a8e71d7d8658e683845036a8cef57e7deb0e67ccc30ede88c32d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cholesterol</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Drugs</topic><topic>Ethics</topic><topic>Females</topic><topic>High density lipoprotein</topic><topic>Internal Medicine</topic><topic>Kidney diseases</topic><topic>Medical records</topic><topic>Nephrology</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Proteins</topic><topic>Standard deviation</topic><topic>Toxins</topic><topic>Uric acid</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mima, Akira</creatorcontrib><creatorcontrib>Gotoda, Hidemasa</creatorcontrib><creatorcontrib>Lee, Shinji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mima, Akira</au><au>Gotoda, Hidemasa</au><au>Lee, Shinji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2024-03-31</date><risdate>2024</risdate><volume>16</volume><issue>3</issue><spage>e57362</spage><epage>e57362</epage><pages>e57362-e57362</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m
. Methods Seven patients with CKD who received dotinurad 0.5 mg to 4 mg per day were studied retrospectively. Changes in UA, eGFR, and urine protein-to-creatinine ratio (UPCR) were analyzed. The observation period was 10.9±2.1 months. Results Serum UA levels were decreased and maintained with dotinurad administration. Nevertheless, there were no improvements noted in renal function. Additionally, no serious adverse effects were identified in any of the patients throughout the observation period. Conclusion Although the sample size in this study was small, our findings demonstrate the efficacy of dotinurad in individuals with advanced CKD who have an eGFR lower than 25 mL/min/1.73 m
.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38694413</pmid><doi>10.7759/cureus.57362</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2024-03, Vol.16 (3), p.e57362-e57362 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11061547 |
| source | PubMed Central; PubMed Central Open Access |
| subjects | Cholesterol Creatinine Diabetes Drugs Ethics Females High density lipoprotein Internal Medicine Kidney diseases Medical records Nephrology Patients Pharmaceuticals Proteins Standard deviation Toxins Uric acid Urine |
| title | Safety and Efficacy of Dotinurad on Uric Acid in Patients With Chronic Kidney Disease With Estimated Glomerular Filtration Rate Below 25 mL/Min/1.73 m |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T04%3A49%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Dotinurad%20on%20Uric%20Acid%20in%20Patients%20With%20Chronic%20Kidney%20Disease%20With%20Estimated%20Glomerular%20Filtration%20Rate%20Below%2025%20mL/Min/1.73%20m&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Mima,%20Akira&rft.date=2024-03-31&rft.volume=16&rft.issue=3&rft.spage=e57362&rft.epage=e57362&rft.pages=e57362-e57362&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.57362&rft_dat=%3Cproquest_pubme%3E3050174341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3062839327&rft_id=info:pmid/38694413&rfr_iscdi=true |